Browsing by Author "İlhan, Osman"
Now showing 1 - 9 of 9
- Results Per Page
- Sort Options
Publication Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA external quality assessment national program results(Ankara Mikrobiyoloji Kulübü, 2018-10-01) Karataylı, Ersin; Soydemir, Ege; Aksoy, Zeynep Buşra; Kızılpınar, Mehtap; Altay Kocak, Aylin; Karataylı, Senem Ceren; Yurdcu, Esra; Yıldırım, Umut; Guriz, Haluk; Bozdayı, Gülendam; Yurdaydın, Cihan; İlhan, Osman; Yıldırım, Yasin; Bozdayı, A. Mithat; Oğuz, Acelya Yalçıntaş; Barış, Ahmet; Alp, Alpaslan; Aksözek, Alper; Sayıner, Arzu; Karagül, Aydan; Ordu, Aylin; İstanbullu, Aye; Otlu, Barış; Arıdoğan, Buket; Aksu, Burak; Buruk, C. Kurtuluş; Karahan, Ceren; Güney, Çakır; Toksöz, Devrim; Yıldırım, Dilara; Çolak, Dilek; Dağlar, Duygu Eren; Fındık, Duygu; Kas, Elif; Calışkan, Emel; Zeyrek, Fadile Yıldız; Arslan, Fatma; Demir, Feyza; Milletli, Fikriye; Kibar, Filiz; Özdinçer, Furkan; Dündar, Gülnür; Arslan, Hande; Ağça, Harun; Aliskan, Hikmet Eda; Güdücuoğlu, Hüseyin; Fidan, Işıl; Akyar, Isin; Afsar, Ilhan; Kaleli, İlknur; Dönmez, İsmail; YanIk, Kemalettin; Midilli, Kenan; çubukcu, Kivanc; Özdemir, Mehmet; Acar, Melek; Yalinay, Meltem; Kuşkucu, Mert Ahmet; Bakırcı, Mustafa Zahir; Aydın, Neriman; Yılmaz, Neziha; Çeken, Nihan; Ziyade, Nihan; Yılmaz, Nisel; Özgümüş, Osman Birol; Gitmişoğlu, Özlem; Demirgan, Recep; Kesli, Recep; Güçkan, Rıdvan; Sertoz, Ruchan; Akgün, Sadık; Aksaray, Sebahat; Tezcan, Seda; Kaygusuz, Sedat; Gökahmetoğlu, Selma; Meşe, Sevim; Bayik, Seyit Ahmet; Akcalı, Sinem; Gürcan, Saban; Karsligil, Tekin; Us, Tercan; Özekinci, Tuncer; Pilgir, Tulin; Aslan, Uğur; Dinc, Ugur; Coşkun, Umut Safiye Say; Çetinkol, Yeliz; Keskin, Yusuf; Ayaydın, Zeynep; Toraman, Zulal Asçı; MOTAKK HBV HCV Calisma Grubu; AĞCA, HARUN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı; 0000-0002-2651-2034; ISU-9626-2023MOTAKK, as a national external quality control program has been launched to evaluate the molecular detection of viral infections including HBV DNA and HCV RNA in molecular microbiology diagnostic laboratories in Turkey. This program is prepared in compliance with ISO 17043:2010 (Conformity assessment general requirements for proficiency testing) standards, and aims to take the place of external quality control programs from abroad, contributing to standardization and accuracy of molecular diagnostic tests in our country. The aim of this study was to evaluate 2015 and 2016 results of the MOTAKK External Quality Control Program for HBV DNA and HCV RNA viral load. The calls were announced on the web page of MOTAKK (www.motakk.org). The quality control samples were sent to participating laboratories in 2015 and 2016. Main stocks were prepared from patients with chronic hepatitis B and C who had viral load detection with reference methods according to WHO reference materials for viral load studies to improve quality control sera. From these main stocks, samples with different viral loads were prepared from dilutions of plasma with HBV, HCV, HAV, HIV, Parvovirus B19 and CMV negative serologic markers. Quality control samples were sent to the participating laboratories along with the negative samples in the cold chain. The laboratories accomplished the related tests within 2-3 weeks and entered their results on the MOTAKK web page. These results were analysed according to ISO 13528 (Statistical methods for use in proficiency testing by interlaboratory comparison) and scoring reports were created by a software developed by MOTAKK and sent to participating labs. Each laboratory evaluated their own results in comparison with the other laboratory results, reassessed the tests via observing the distance from the mean result and the reference values. The number of laboratories participating in the HBV DNA and HCV RNA external quality control program was 70-73 in 2015-2016. Participants were able to comply with the program tools, registering, entering results and receiving the results reports problem. In HBV panel, 72.6-89.1% and 84.7-90.3% of the participant laboratories were in 1 standard deviation (SD) in 2015-2016, respectively. In HCV panel, 70.8-89.1% and 84.7-90.3% of the participant laboratories were in 1 SD in 2015-2016, respectively. A national external quality control program for HBV DNA and HCV RNA in Turkey has been prepared for the first time with this project and implemented successfully. All the data provided in the MOTAKK external quality control program final report, compensate all the data provided by the quality control program final reports from abroad; additionally, the report allows comparison of used technologies and commercial products.Item Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: Updated results with 2 years of follow-up(Taylor & Francis, 2018-11-26) Saydam, Güray; Haznedaroğlu, İbrahim Celalettin; Kaynar, Leylagül; Yavuz, Akif S.; Ali, Rıdvan; Güvenç, Birol; Akay, Olga M.; Başlar, Zafer; Özbek, Uğur; Sönmez, Mehmet; Aydın, Demet; Pehlivan, Mustafa; Ündar, Bülent; Dağdaş, Simten; Ayyıldız, Orhan; Akın, Gülnur; Dağ, İlkiz M.; İlhan, Osman; Ali, Rıdvan; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; GXD-8209-2022; 7201813027Objectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods: Patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase (CML-CP; N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR; BCR-ABL1 <= 0.1% on the International Scale [BCR-ABL1(IS)]) by 12 months, was previously reported (66.1% [80% CI, 59.7%-72.0%]). ClinicalTrials.gov identifier NCT01274351 Results: By 24 months, 83.0% of patients achieved MMR, and 50.9% achieved MR4.5 (BCR-ABL1(IS) <= 0.0032%). Safety results at 24 months were consistent with those at 12 months. No additional deaths or disease progressions to accelerated phase/blast crisis were observed between 12 and 24 months. Discussion: Treatment with nilotinib 300 mg twice daily for 2 years provided high MMR with a good safety/tolerability profile in newly diagnosed CML-CP patients in Turkey. Assessment of MMR across time points showed increasing rates through 18 months, after which as lower rate of increase was observed. The safety profile of nilotinib 300 mg twice daily with 24 months of follow-up was similar to that observed at 12 months, and no new safety concerns were identified. These efficacy and safety findings are consistent with the results from the 12-month analysis of this study and from previous nilotinib studies. These findings support nilotinib as an option for frontline treatment of CML-CP. Conclusion: Frontline nilotinib treatment provided sustained efficacy, with good tolerability, over 24 months in newly diagnosed CML-CP patients.Item Kök hücre nakli hastalarında tamamlayıcı ve alternatif tedavi kullanımı(Uludağ Üniversitesi, 2011-12-16) Akkuş, Yeliz; Akdemir, Nuran; Göker, Hakan; Aksu, Salih; Sucak, Gülsan A.; Özet, Gülsüm; İlhan, Osman; Karacan, Yasemin; Tekinalp, Atakan; Özkocaman, Vildan; Ali, Rıdvan; Özkalemkaş, Fahir; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Bilim Dalı.Bu çalışma kök hücre nakli yapılan hastaların nakil öncesi ya da nakil sonrası TAT uygulamalarının değerlendirilmesi amacıyla tanımlayıcı olarak yapılmıştır. Veriler Ankara’da bulunan 5 hastanede tedavi gören 153 hastadan toplanmıştır. Veri toplama formu sosyo-demografik özellikler ve geçen ve bir önceki yıllardaki ilik nakillerinde TAT kullanımına ilişkin bilgileri kapsamaktadır. Hastaların TAT rak %48.4’ünün şifalı bitkisel ürünleri, %28.1’inin dini aktiviteleri (dualar) kullandığı belirlenmiştir. Hastaların sıklıkla bitkisel ürün olarak ısırgan otunu (%69.0) ,hayvansal ürün olarak ise kaplumbağa kanını kullandığı saptandı. Hastalar çoğunlukla tedavi edici, gevşetici ve manevi güç olarak TAT kullandığını belirtmiştir. Hastaların %79.0’u doktorları ile TAT kullanımlarına ilişkin tartışmadıklarını/danışmadıklarını belirtmiştir. Bu çalışmanın bulgularının diğer çalışmalardakilerle benzer olduğu saptanmıştır.Item Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF(Springernature, 2009-12) Topçuoǧlu, Pervin; Beksac, M. S.; Özcan, Muhit; Arat, Mutlu; Bykl, Z.; Bakanay, Şule Mine; İlhan, Osman; Gürman, Günhan; Arslan, Önder; Demirer, Taner; Özçelik, Tülay; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı.; 7005424333The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobilization with CE (CY 4 g/m(2) on day 1 and etoposide 200 mg/m(2) on days 1-3). The rhG-CSF dose was 10 mu g/kg/day for all patients. Both groups were comparable in terms of sex, age and number of previously given different chemotherapy regimens. Duration of neutropenia, CD34(+) cell count on the first day of apheresis and numbers of aphereses were not statistically different between the two arms. However, the number of doses of rhG-CSF up to the first cycle of apheresis procedures was significantly lower in the late group than in the early group (P-0.005). The median number of total CD34(+) cells collected was 10.54 x 10(6)/kg (range 0.11-37.27) in the early group and 10.81 x 10(6)/kg (range 0.17-49.83) in the late group of rhG-CSF (P-0.781). We conclude that PBSC mobilization after late use of rhG-CSF is an effective approach and therefore, in routine clinical practice, late rhG-CSF may be used for PBSC collections after chemotherapybased mobilization regimens in this cost-conscious era.Item Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase(Taylor & Francis, 2016-07-28) Saydam, Güray; Haznedaroğlu, İbrahim Celalettin; Kaynar, Leylagül; Yavuz, Akif S.; Güvenç, Birol; Akay, Olga M.; Başlar, Zafer; Özbek, Uğur; Sönmez, Mehmet; Aydın, Demet; Pehlivan, Mustafa; Ündar, Bülent; Dağdaş, Simten; Ayyıldız, Orhan; Akkaynak, Diyar Z.; Dağ, İlkız M.; İlhan, Osman; Ali, Rıdvan; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; 7201813027Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL10.1% on the International Scale [BCR-ABL1(IS)]) by 12months.Methods: Patients with newly diagnosed CML-CP were treated with nilotinib 300mg twice daily. This analysis was based on the first 12months of follow-up in a 24-month study.Results and Conclusions: Of 112 patients enrolled, 66.1% (80% CI, 59.7-72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1(IS) 0.0032%) by 12months. During the first year of treatment, 1 patient progressed to blast crisis and 2 patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides. These results support the use of nilotinib 300mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP.Item Renal amiloidosiste serum immun kompleksler(Uludağ Üniversitesi, 1990) İlhan, Osman; Özdemir, F. Nurhan; Özdemir, A. İlhanAnkara Tıp Fakültesi Nefroloji Bilim Dalında, tanılan histolojik olarak konulmuş olan 32 renal amiloidozisli hasta ile 20 normal kişide serum immün kompleks değerleri ölçüldü. Serum immün kompleks değerleri amiloidozisli hastalarda normale göre belirgin olarak yüksek bulundu. Ayrıca primer, sekonder, ailevi akdeniz humması ve nedeni kesinlikle saptanamayan hastalar kendi aralarında karşılaştırıldı. Bu gruplar arasında, serum immün kompleks yoğunluğu açısından anlamlı bir farklılık bulunamadı.Item Sağlıklı bireylerde ayak bileği evertör ve dorsal fleksör kas gruplarına yönelik elektromyostimulasyon uygulamasının kas reaksiyon zamanı ve propriosepsiyon üzerine etkileri(Uludağ Üniversitesi, 2018) İlhan, Osman; Akova, Bedrettin; Uludağ Üniversitesi/Tıp Fakültesi/Spor Hekimliği Anabilim Dalı.Bu çalışmada sağlıklı bireylerde tibialis anterior (TA) ve peroneus longus (PL) kaslarına yönelik uygulanan iki farklı elektromyostimulasyon protokolünün sensorimotor kontrol üzerine etkilerini araştırmayı amaçladık. Otuz altı sağlıklı rekreasyonel sporcu rastgele olacak şekilde standart elektromyostimülasyon (SE) (n = 13), kişisel elektromyostimülasyon (akım genişliği reaksiyon zamanına göre hesaplandı) (KE) (n = 13) ve kontrol (n = 10) gruplarına ayrıldı. SE ve KE gruplarına 6 hafta, haftada 3 gün, günde 20 dakika olacak şekilde yapılan elektrostimülasyon uygulaması PL ve TA kasları üzerine gelecek şekilde uygulandı. Katılımcılara ön testler olarak inversiyon yönünde 10° ve 20°, plantarfleksiyon yönünde ise 15° ve 30° açılarda aktif ve pasif eklem pozisyon hissi testleri, kinestezi testi, plantarflexor, dorsalflexor, invertor ve evertor kaslara yönelik izometrik kuvvet testi, 15° ve 30° ani inversiyon simülasyon platformunda nötral ve plantarfleksiyon pozisyonlarında kas reaksiyon zamanı ölçümleri ve yıldız denge testi ile dinamik denge ölçümü yapılmıştır. 6 haftalık elektrostimülasyon sonrasında testler tekrarlanmıştır. Elektrostimülasyon sonrasında her iki elektrostimülasyon grubunda plantarfleksiyonda peroneus longus ve tibialis anterior kas reaksiyon zamanlarında anlamlı bir kısalma (p<0.01-0.001) ve yıldız denge testinde dinamik dengede anlamlı bir artış (p<0.05-0.001) gösterilirken elektrostimülasyon grupları arasında fark saptanmadı (p>0.05). Aynı zamanda eklem pozisyon hissi, kinestezi ve izometrik kuvvet değerlerinde anlamlı bir farka rastlanmadı (p>0.05) Bu çalışma ile, dorsiflexor ve evertor kasların elektromyostimülasyonunun kas reaksiyon süresi ve dinamik dengeye olumlu etkiler yaptığı ortaya konmuştur. Sonuç olarak, sağlıklı ve fonksiyonel ayak bileği instabilitesi olan bireylerin ayak bileği yaralanmalarından korunması için rehabilitasyon programlarına elektrostimülasyonun eklenmesinin faydalı olacağını söylemek mümkündür.Item Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial(Pergamon-Elsevier Science, 2011-03) Beksaç, Meral; Özcan, Muhit; Özçebe, Osman; Bayık, Mahmut; Paydaş, Semra; Büyükaşık, Yahya; İlhan, Osman; Gürman, Günhan; Uysal, Akın; Akan, Hamdi; Soydan, Ender Akcağlayan; Ali, Ridvan; Özçelik, Tülay; Özkalemkaş, Fahir; Tunalı, Ahmet; Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; AAG-8495-2021; 7201813027; 7005424333; 6601912387This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of G-CSF as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov.NCT00820976). Patients' characteristics were similar in both arms. G-CSF improved severity and duration of leukopenia. Three-year OS were similar (25.6 +/- 5.1% vs. 31.8 +/- 5.6%) in both arms except for patients with myeloblastic features. Significant factors for better survival were the use of G-CSF (p = 0.049), female sex (p = 0.05) and single induction cycle (p < 0.001) in multivariate analysis. Female patients performed better than male patients. Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis.Publication The effect of static stretching of peroneal and tibialis anterior muscles on reaction time a randomized controlled study(Lippincott Williams & Wilkins, 2019-02-01) Arslan, Gufat; Şekir, Ufuk; ŞEKİR, UFUK; İlhan, Osman; Akova, Bedrettin; AKOVA, BEDRETTİN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0003-2735-8697; 0000-0003-1044-8805; AAM-4348-2020; AAI-4550-2021; ABC-8182-2021Objective: The aim of this study was to investigate the acute and chronic effects of static stretching on peroneal and tibialis anterior reaction characteristics.Design: All 23 participants who volunteered for this study were randomly divided into static (n = 12) and control (n = 11) groups. The subjects in the static stretching group performed stretching exercises for the ankle evertor and dorsiflexor muscles 5 days a week for 6 wks. Peroneal and tibialis anterior muscle reaction characteristics were evaluated at the beginning (2 times for acute effect) and end of this period. Electromyographic activity parameters of the muscles were measured using an ankle inversion tilting platform that simulated a sudden ankle inversion. The following were the four different ankle inversion conditions: (a) ankle-neutral, 15-degree inversion; (b) ankle-neutral, 30-degree inversion; (c) ankle-20-degree plantarflexion, 15-degree inversion; and (d) ankle-20-degree plantarflexion, 30-degree inversion.Results: Either in terms of acute or chronic effects, no significant differences were found after static stretching exercises for peroneal and tibialis anterior muscle reaction time, reaction duration, and muscle activity evaluated in four positions on the ankle inversion simulation platform (P > 0.05).Conclusions: In light of these results, it is possible to state that the short duration of static stretching exercises can still be applied before sports activities.